RO7058584 in Glaucoma or Ocular Hypertension

Phase 1, randomised, double-blind trial of RO7058584 in primary open-angle glaucoma (POAG) and ocular hypertension (4 arms), sponsored by Roche. Primary endpoints: Incidence, Severity, and Causal Relationship of Ocular and Systemic Adverse Events up to 12 weeks, Incidence of Abnormal Laboratory Findings up to 12 weeks and 4 more. Started Oct 2017; status: completed.